Life
Briefing: FTC Strikes Proposed Deal with CVS Over Insulin Price Manipulation
Strategic angle: Settlement expected to save Americans up to $7 billion in out-of-pocket costs over the next decade.
editorial-staff
1 min read
Updated 18 days ago
The Federal Trade Commission (FTC) has proposed a settlement with CVS concerning allegations that its pharmacy benefit manager (PBM) manipulated insulin prices. This manipulation reportedly impeded access to affordable insulin for consumers.
The settlement is projected to save Americans up to $7 billion in out-of-pocket costs over the next ten years, indicating significant implications for healthcare affordability.
If implemented, this agreement may lead to structural changes in how insulin pricing is managed, potentially enhancing access and reducing financial burdens on consumers reliant on this essential medication.